Related Experiment Video

Updated: May 4, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.4K

Suicidal Thoughts and Self-injurious Behavior Associated With Glucagon- Like Peptide-1 Receptor Agonists - A Review

Naina Mohamed Pakkir Maideen1, Sultan Al Rashid2

  • 1Pharmacologist, Dubai Academic Health Corporation, Dubai, UAE.

Current Drug Safety
|May 20, 2024
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) receptor agonists, used for diabetes and weight loss, are linked to serious side effects like suicidal thoughts. Regulatory agencies warn against misuse, urging physician consultation for safe weight management.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Public Health

Background:

  • Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for type 2 diabetes and weight management.
  • Recent trends show misuse of these antidiabetic medications for cosmetic weight loss purposes.
  • This misuse raises concerns regarding potential serious adverse events.

Purpose of the Study:

  • To review and highlight serious side effects associated with GLP-1 receptor agonists.
  • To focus on adverse events reported by regulatory agencies, particularly concerning misuse.
  • To inform healthcare professionals and patients about associated risks.

Main Methods:

  • Comprehensive literature search across major scientific databases (Medline/PubMed/PMC, Google Scholar, Scopus, Web of Science, Embase, etc.).
  • Inclusion of pharmacovigilance analyses and official notifications from regulatory bodies.
  • Identification of studies detailing serious side effects linked to GLP-1 receptor agonist use.

Main Results:

  • Pharmacovigilance data and regulatory notifications indicate a link between GLP-1 receptor agonists and suicidal ideation.
  • Self-injurious behaviors have also been documented as potential serious side effects.
  • These findings underscore the risks associated with both therapeutic use and misuse.

Conclusions:

  • Healthcare providers must be vigilant regarding the potential for GLP-1 receptor agonist-associated suicidal thoughts and self-injurious behavior.
  • Patients are strongly advised against the misuse or abuse of these medications for weight loss.
  • Consultation with a healthcare professional is essential before initiating any GLP-1 receptor agonist therapy.
Keywords:
GLP-1 receptor agonistsdepressionpharmacovigilanceself-injurious behavior.suicidal thoughts

More Related Videos

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

9.7K
Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

5.8K

Related Concept Videos

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.8K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
45